New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 1, 2013
08:03 EDTAFFY, TKPYYAnemia drug had side effects soon after it went on the market, WSJ reports
As the FDA evaluates the anemia drug Omontys, used in kidney dialysis patients, life-threatening reactions to it began appearing within months of when the treatment went on the market, according to a review of regulatory records, reports the Wall Street Journal. The drug, from Affymax Inc. (AFFY) and Takeda Pharmaceutical Co. (TKPYY), was linked to allergic reactions and respiratory distress beginning in August 2012, soon after it went on the U.S. market in late April. Reference Link
News For AFFY;TKPYY From The Last 14 Days
Check below for free stories on AFFY;TKPYY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 16, 2014
10:34 EDTTKPYYApricus Biosciences reports Takeda accepts first shipment of Vitaros
Subscribe for More Information
April 8, 2014
09:03 EDTTKPYYSeattle Genetics to receive milestone payments from Takeda on Adcetris
Subscribe for More Information
08:39 EDTTKPYYTakeda to challenge award of $6B in punitive damages, Lilly ordered to pay $3B
Takeda Pharmaceuticals (TKPYY) announced last night that in the case of Terrence Allen, et al. v. Takeda Pharmaceuticals North America the jury found in favor of the plaintiffs and awarded $1.475M in compensatory damages. The allocation of liability was 75% Takeda and 25% Eli Lilly (LLY). The jury also awarded $6B in punitive damages from Takeda and $3B from co-defendant, Eli Lilly. “Takeda respectfully disagrees with the verdict and we intend to vigorously challenge this outcome through all available legal means, including possible post-trial motions and an appeal. We have empathy for the Allens, but we believe the evidence did not support a finding that ACTOS caused his bladder cancer. We also believe we demonstrated that Takeda acted responsibly with regard to ACTOS,” said Kenneth Greisman, senior vice president, general counsel, Takeda. Reference Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use